Strengthens the Novartis oncology pipeline with two lead ADC assets and a broader payload platform with potential impact ...

Basel, July 2, 2026 – Novartis today announced that the European Commission (EC) has approved Itvisma ® (onasemnogene ...

Explore opportunities with Novartis and Sandoz below. For additional roles with Novartis Gene Therapies (formerly AveXis) visit the GTx Career Search.

Board member since March 2023 Nationality: British/American | Year of birth: 1964 A scientist by training, John D. Young has over 35 years of experience in the healthcare industry and brings a wealth ...

Transforming the treatment and healthcare system landscape using early interventions, pioneering treatments, and innovative partnerships to avoid preventable mortality from cardiovascular disease (CVD ...

Join our network of bright and curious minds What makes building a career here so rewarding? It’s being part of a community of smart, dedicated people. Professionals you can admire, learn from, and ...

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the ...

“One of the things I love about working for Novartis is the trust the company has in us. They allow us to work flexibly – so that we can balance our lives, our families and making an impact with our ...

Novartis uses the open-source Drupal content management framework for many key websites, including our flagship global site Novartis.com, main country sites, portals for healthcare professionals, and ...

Age-related diseases, including neurodegenerative diseases and cardiovascular and metabolic diseases, account for a substantial and rising portion of the global health burden. DARe scientists are ...

The mental health and wellbeing of our people is fundamental to who we are at Novartis. As an extension of our purpose to improve and extend people’s lives, we are committed to supporting our people ...